In this regard, two recent studies have shown that mutations in RB1 and p53, which occur in high risk prostate cancer patients, leads to significant elevation of SOX2 in an animal model of prostate cancer and in the androgen dependent prostatic tumor cell line LNCaP [120, 121]. This evidence concerns the gene TP53 and Familial prostate cancer.